Calcitonin directly attenuates collagen type II degradation by inhibition of matrix metalloproteinase expression and activity in articular chondrocytes

Osteoarthritis and Cartilage

Volumn 14, Issue 8, 2006, Pages 759-768

  Sondergaard, B C ^a   Wulf, H ^a   Henriksen, K ^b   Schaller, S ^b   Oestergaard, S ^a   Qvist, P ^a   Tanko L B ^c   Bagger, Y Z ^c   Christiansen, C ^c   Karsdal, M A ^a,b  

^a NORDIC BIOSCIENCE A S   (Denmark)

^b Pharmos Bioscience   (Denmark)

^c CENTER FOR CLINICAL AND BASIC RESEARCH   (Denmark)

Author keywords

Articular cartilage degradation; Calcitonin; Calcitonin receptor; CTX II; Matrix metalloproteinases; Ovariectomized rats

Indexed keywords

CALCITONIN; CALCITONIN RECEPTOR; CARBOXY TERMINAL TELOPEPTIDE; COLLAGEN TYPE 2; CYCLIC AMP; MATRIX METALLOPROTEINASE; ONCOSTATIN M; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL CELL; ANIMAL TISSUE; ARTICLE; ARTICULAR CARTILAGE; CARTILAGE CELL; CARTILAGE DEGENERATION; CELL ISOLATION; CHONDROPROTECTION; COLLAGEN DEGRADATION; CONCENTRATION RESPONSE; CONTROLLED STUDY; COW; DOSE RESPONSE; ENZYME ACTIVITY; EX VIVO STUDY; EXPERIMENTAL MODEL; EXPLANT; FEMALE; IMMUNOHISTOCHEMISTRY; IN VIVO STUDY; INHIBITION KINETICS; MOUSE; NONHUMAN; OSTEOARTHRITIS; OSTEOLYSIS; OVARIECTOMY; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN INDUCTION; PROTEIN LOCALIZATION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;

ANIMALS; BIOLOGICAL MARKERS; CALCITONIN; CARTILAGE, ARTICULAR; CATTLE; CHONDROCYTES; COLLAGEN TYPE I; COLLAGEN TYPE II; EXTRACELLULAR MATRIX; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; MATRIX METALLOPROTEINASES; ONCOSTATIN M; OVARIECTOMY; PEPTIDES; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, CALCITONIN; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; TUMOR NECROSIS FACTOR-ALPHA;

EID: 33745622400     PISSN: 10634584     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.joca.2006.01.014     Document Type: Article

References (67)

1. Elders M.J. The increasing impact of arthritis on public health. J Rheumatol Suppl 60 (2000) 6-8
2. Reginster J.Y., Deroisy R., Rovati L.C., Lee R.L., Lejeune E., Bruyere O., et al. Long-term effects of glucosamine sulphate on osteoarthritis progression: a randomised, placebo-controlled clinical trial. Lancet 357 (2001) 251-256
3. Felson D.T., and Neogi T. Osteoarthritis: is it a disease of cartilage or of bone?. Arthritis Rheum 50 (2004) 341-344
4. Hayami T., Pickarski M., Wesolowski G.A., McLane J., Bone A., Destefano J., et al. The role of subchondral bone remodeling in osteoarthritis: reduction of cartilage degeneration and prevention of osteophyte formation by alendronate in the rat anterior cruciate ligament transection model. Arthritis Rheum 50 (2004) 1193-1206
5. Cranney A., Tugwell P., Zytaruk N., Robinson V., Weaver B., Shea B., et al. Meta-analyses of therapies for postmenopausal osteoporosis. VI. Meta-analysis of calcitonin for the treatment of postmenopausal osteoporosis. Endocr Rev 23 (2002) 540-551
6. Manicourt D.H., Devogelaer J.P., Azria M., and Silverman S. Rationale for the potential use of calcitonin in osteoarthritis. J Musculoskelet Neuronal Interact 5 (2005) 285-293
7. Khaldi L., Karachalios T., Galanos A., and Lyritis G.P. Morphometric changes in the epiphyseal plate of the growing and young adult male rat after long-term salmon calcitonin administration. Calcif Tissue Int 76 (2005) 426-432
8. Di Nino D.L., and Linsenmayer T.F. Positive regulation of endochondral cartilage growth by perichondrial and periosteal calcitonin. Endocrinology 144 (2003) 1979-1983
9. Burch W.M., and Corda G. Calcitonin stimulates maturation of mammalian growth plate cartilage. Endocrinology 116 (1985) 1724-1728
10. Franchimont P., Bassleer C., Henrotin Y., Gysen P., and Bassleer R. Effects of human and salmon calcitonin on human articular chondrocytes cultivated in clusters. J Clin Endocrinol Metab 69 (1989) 259-266
11. Hellio M.P., Peschard M.J., Cohen C., Richard M., and Vignon E. Calcitonin inhibits phospholipase A2 and collagenase activity of human osteoarthritic chondrocytes. Osteoarthritis Cartilage 5 (1997) 121-128
12. Behets C., Williams J.M., Chappard D., Devogelaer J.P., and Manicourt D.H. Effects of calcitonin on subchondral trabecular bone changes and on osteoarthritic cartilage lesions after acute anterior cruciate ligament deficiency. J Bone Miner Res 19 (2004) 1821-1826
13. El Hajjaji H., Williams J.M., Devogelaer J.P., Lenz M.E., Thonar E.J., and Manicourt D.H. Treatment with calcitonin prevents the net loss of collagen, hyaluronan and proteoglycan aggregates from cartilage in the early stages of canine experimental osteoarthritis. Osteoarthritis Cartilage 12 (2004) 904-911
14. Ishikawa T., Nishigaki F., Christgau S., Noto T., Mo J., From N., et al. Cartilage destruction in collagen induced arthritis assessed with a new biochemical marker for collagen type II C-telopeptide fragments. J Rheumatol 31 (2004) 1174-1179
15. Christgau S., Garnero P., Fledelius C., Moniz C., Ensig M., Gineyts E., et al. Collagen type II C-telopeptide fragments as an index of cartilage degradation. Bone 29 (2001) 209-215
16. Karsdal M.A., Hjorth P., Henriksen K., Kirkegaard T., Nielsen K.L., Lou H., et al. Transforming growth factor-beta controls human osteoclastogenesis through the p38 MAPK and regulation of RANK expression. J Biol Chem 278 (2003) 44975-44987
17. Nicholson G.C., Malakellis M., Collier F.M., Cameron P.U., Holloway W.R., Gough T.J., et al. Induction of osteoclasts from CD14-positive human peripheral blood mononuclear cells by receptor activator of nuclear factor kappaB ligand (RANKL). Clin Sci (Lond) 99 (2000) 133-140
18. Chomczynski P., and Sacchi N. Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. Anal Biochem 162 (1987) 156-159
19. Tanko L.B., Bagger Y.Z., Alexandersen P., Devogelaer J.P., Reginster J.Y., Chick R., et al. Safety and efficacy of a novel salmon calcitonin (sCT) technology-based oral formulation in healthy postmenopausal women: acute and 3-month effects on biomarkers of bone turnover. J Bone Miner Res 19 (2004) 1531-1538
20. Shen Y., Li M., and Wronski T.J. Calcitonin provides complete protection against cancellous bone loss in the femoral neck of ovariectomized rats. Calcif Tissue Int 60 (1997) 457-461
21. Giavaresi G., Fini M., Gnudi S., Aldini N.N., Rocca M., Carpi A., et al. Comparison of calcitonin, alendronate and fluorophosphate effects on ovariectomized rat bone. Biomed Pharmacother 55 (2001) 397-403
22. Shen Y., Li M., and Wronski T.J. Skeletal effects of calcitonin treatment and withdrawal in ovariectomized rats. Calcif Tissue Int 58 (1996) 263-267
23. Li M., Shen Y., Burton K.W., DeLuca P.P., Mehta R.C., Baumann B.D., et al. A comparison of the skeletal effects of intermittent and continuous administration of calcitonin in ovariectomized rats. Bone 18 (1996) 375-380
24. Buclin T., Cosma R.M., Burckhardt P., Azria M., and Attinger M. Bioavailability and biological efficacy of a new oral formulation of salmon calcitonin in healthy volunteers. J Bone Miner Res 17 (2002) 1478-1485
25. Hoegh-Andersen P., Tanko L.B., Andersen T.L., Lundberg C.V., Mo J.A., Heegaard A.M., et al. Ovariectomized rats as a model of postmenopausal osteoarthritis: validation and application. Arthritis Res Ther 6 (2004) R169-R180
26. Kuestner R.E., Elrod R.D., Grant F.J., Hagen F.S., Kuijper J.L., Matthewes S.L., et al. Cloning and characterization of an abundant subtype of the human calcitonin receptor. Mol Pharmacol 46 (1994) 246-255
27. Christgau S., Tanko L.B., Cloos P.A., Mouritzen U., Christiansen C., Delaisse J.M., et al. Suppression of elevated cartilage turnover in postmenopausal women and in ovariectomized rats by estrogen and a selective estrogen-receptor modulator (SERM). Menopause 11 (2004) 508-518
28. Hui W., Rowan A.D., Richards C.D., and Cawston T.E. Oncostatin M in combination with tumor necrosis factor alpha induces cartilage damage and matrix metalloproteinase expression in vitro and in vivo. Arthritis Rheum 48 (2003) 3404-3418
29. Mackay A.M., Beck S.C., Murphy J.M., Barry F.P., Chichester C.O., and Pittenger M.F. Chondrogenic differentiation of cultured human mesenchymal stem cells from marrow. Tissue Eng 4 (1998) 415-428
30. Johnstone B., Hering T.M., Caplan A.I., Goldberg V.M., and Yoo J.U. In vitro chondrogenesis of bone marrow-derived mesenchymal progenitor cells. Exp Cell Res 238 (1998) 265-272
31. Karsdal M.A., Larsen L., Engsig M.T., Lou H., Ferreras M., Lochter A., et al. Matrix metalloproteinase-dependent activation of latent transforming growth factor-beta controls the conversion of osteoblasts into osteocytes by blocking osteoblast apoptosis. J Biol Chem 277 (2002) 44061-44067
32. Garnero P., Ferreras M., Karsdal M.A., NicAmhlaoibh R., Risteli J., Borel O., et al. The type I collagen fragments ICTP and CTX reveal distinct enzymatic pathways of bone collagen degradation. J Bone Miner Res 18 (2003) 859-867
33. Dean D.D., Martel-Pelletier J., Pelletier J.P., Howell D.S., and Woessner Jr. J.F. Evidence for metalloproteinase and metalloproteinase inhibitor imbalance in human osteoarthritic cartilage. J Clin Invest 84 (1989) 678-685
34. Martel-Pelletier J., Alaaeddine N., and Pelletier J.P. Cytokines and their role in the pathophysiology of osteoarthritis. Front Biosci 4 (1999) D694-D703
35. Saklatvala J. Tumour necrosis factor alpha stimulates resorption and inhibits synthesis of proteoglycan in cartilage. Nature 322 (1986) 547-549
36. Cawston T.E., Curry V.A., Summers C.A., Clark I.M., Riley G.P., Life P.F., et al. The role of oncostatin M in animal and human connective tissue collagen turnover and its localization within the rheumatoid joint. Arthritis Rheum 41 (1998) 1760-1771
37. Langdon C., Kerr C., Hassen M., Hara T., Arsenault A.L., and Richards C.D. Murine oncostatin M stimulates mouse synovial fibroblasts in vitro and induces inflammation and destruction in mouse joints in vivo. Am J Pathol 157 (2000) 1187-1196
38. Brennan F.M., Browne K.A., Green P.A., Jaspar J.M., Maini R.N., and Feldmann M. Reduction of serum matrix metalloproteinase 1 and matrix metalloproteinase 3 in rheumatoid arthritis patients following anti-tumour necrosis factor-alpha (cA2) therapy. Br J Rheumatol 36 (1997) 643-650
39. Catrina A.I., Lampa J., Ernestam S., af K.E., Bratt J., Klareskog L., et al. Anti-tumour necrosis factor (TNF)-alpha therapy (etanercept) down-regulates serum matrix metalloproteinase (MMP)-3 and MMP-1 in rheumatoid arthritis. Rheumatology (Oxford) 41 (2002) 484-489
40. Manicourt D.H., Poilvache P., Van Egeren A., Devogelaer J.P., Lenz M.E., and Thonar E.J. Synovial fluid levels of tumor necrosis factor alpha and oncostatin M correlate with levels of markers of the degradation of crosslinked collagen and cartilage aggrecan in rheumatoid arthritis but not in osteoarthritis. Arthritis Rheum 43 (2000) 281-288
41. Hui W., Cawston T., and Rowan A.D. Transforming growth factor beta 1 and insulin-like growth factor 1 block collagen degradation induced by oncostatin M in combination with tumour necrosis factor alpha from bovine cartilage. Ann Rheum Dis 62 (2003) 172-174
42. Van den Berg W.B. Lessons from animal models of arthritis. Curr Rheumatol Rep 4 (2002) 232-239
43. Bell M.C., Carroll G.J., Chapman H.M., Mills J.N., and Hui W. Oncostatin M induces leukocyte infiltration and cartilage proteoglycan degradation in vivo in goat joints. Arthritis Rheum 42 (1999) 2543-2551
44. Helminen H.J., Saamanen A.M., Salminen H., and Hyttinen M.M. Transgenic mouse models for studying the role of cartilage macromolecules in osteoarthritis. Rheumatology (Oxford) 41 (2002) 848-856
45. Lohmander L.S., Atley L.M., Pietka T.A., and Eyre D.R. The release of crosslinked peptides from type II collagen into human synovial fluid is increased soon after joint injury and in osteoarthritis. Arthritis Rheum 48 (2003) 3130-3139
46. Lohmander L.S., Hoerrner L.A., and Lark M.W. Metalloproteinases, tissue inhibitor, and proteoglycan fragments in knee synovial fluid in human osteoarthritis. Arthritis Rheum 36 (1993) 181-189
47. Lohmander L.S. Markers of altered metabolism in osteoarthritis. J Rheumatol Suppl 70 (2004) 28-35
48. Lohmander L.S., Ionescu M., Jugessur H., and Poole A.R. Changes in joint cartilage aggrecan after knee injury and in osteoarthritis. Arthritis Rheum 42 (1999) 534-544
49. Firestein G.S., Paine M.M., and Littman B.H. Gene expression (collagenase, tissue inhibitor of metalloproteinases, complement, and HLA-DR) in rheumatoid arthritis and osteoarthritis synovium. Quantitative analysis and effect of intraarticular corticosteroids. Arthritis Rheum 34 (1991) 1094-1105
50. Lark M.W., Bayne E.K., Flanagan J., Harper C.F., Hoerrner L.A., Hutchinson N.I., et al. Aggrecan degradation in human cartilage. Evidence for both matrix metalloproteinase and aggrecanase activity in normal, osteoarthritic, and rheumatoid joints. J Clin Invest 100 (1997) 93-106
51. Chambers M.G., Cox L., Chong L., Suri N., Cover P., Bayliss M.T., et al. Matrix metalloproteinases and aggrecanases cleave aggrecan in different zones of normal cartilage but colocalize in the development of osteoarthritic lesions in STR/ort mice. Arthritis Rheum 44 (2001) 1455-1465
52. Lohmander L.S. Articular cartilage and osteoarthrosis. The role of molecular markers to monitor breakdown, repair and disease. J Anat 184 Pt 3 (1994) 477-492
53. Bank R.A., Soudry M., Maroudas A., Mizrahi J., and TeKoppele J.M. The increased swelling and instantaneous deformation of osteoarthritic cartilage is highly correlated with collagen degradation. Arthritis Rheum 43 (2000) 2202-2210
54. LeRoux M.A., Arokoski J., Vail T.P., Guilak F., Hyttinen M.M., Kiviranta I., et al. Simultaneous changes in the mechanical properties, quantitative collagen organization, and proteoglycan concentration of articular cartilage following canine meniscectomy. J Orthop Res 18 (2000) 383-392
55. Nelson F., Dahlberg L., Laverty S., Reiner A., Pidoux I., Ionescu M., et al. Evidence for altered synthesis of type II collagen in patients with osteoarthritis. J Clin Invest 102 (1998) 2115-2125
56. Karsdal M.A., Fjording M.S., Foged N.T., Delaisse J.M., and Lochter A. Transforming growth factor-beta-induced osteoblast elongation regulates osteoclastic bone resorption through a p38 mitogen-activated protein kinase- and matrix metalloproteinase-dependent pathway. J Biol Chem 276 (2001) 39350-39358
57. Lemaitre V., Jungbluth A., and Eeckhout Y. The recombinant catalytic domain of mouse collagenase-3 depolymerizes type I collagen by cleaving its aminotelopeptides. Biochem Biophys Res Commun 230 (1997) 202-205
58. Elnemr A., Yonemura Y., Bandou E., Kinoshita K., Kawamura T., Takahashi S., et al. Expression of collagenase-3 (matrix metalloproteinase-13) in human gastric cancer. Gastric Cancer 6 (2003) 30-38
59. D'Angelo M., Billings P.C., Pacifici M., Leboy P.S., and Kirsch T. Authentic matrix vesicles contain active metalloproteases (MMP). A role for matrix vesicle-associated MMP-13 in activation of transforming growth factor-beta. J Biol Chem 276 (2001) 11347-11353
60. Takahashi S., Goldring S., Katz M., Hilsenbeck S., Williams R., and Roodman G.D. Downregulation of calcitonin receptor mRNA expression by calcitonin during human osteoclast-like cell differentiation. J Clin Invest 95 (1995) 167-171
61. Susa M., Luong-Nguyen N.H., Cappellen D., Zamurovic N., and Gamse R. Human primary osteoclasts: in vitro generation and applications as pharmacological and clinical assay. J Transl Med 2 (2004) 6
62. Manicourt D.H., Altman R.D., Williams J.M., Devogelaer J.P., Druetz-Van Egeren A., Lenz M.E., et al. Treatment with calcitonin suppresses the responses of bone, cartilage, and synovium in the early stages of canine experimental osteoarthritis and significantly reduces the severity of the cartilage lesions. Arthritis Rheum 42 (1999) 1159-1167
63. Oestergaard S., Sondergaard B.C., Hoegh-Andersen P., Tanko L.B., Qvist P., Christiansen C., et al. Loss of estrogen leads to cartilage degradation. Osteoarthritis Cartilage 13 Suppl A (2005) S146
64. Reijman M., Hazes J.M., Bierma-Zeinstra S.M., Koes B.W., Christgau S., Christiansen C., et al. A new marker for osteoarthritis: cross-sectional and longitudinal approach. Arthritis Rheum 50 (2004) 2471-2478
65. Bagger Y.Z., Tanko L.B., Alexandersen P., Karsdal M.A., Olson M., Mindeholm L., et al. Oral salmon calcitonin induced suppression of urinary collagen type II degradation in postmenopausal women: a new potential treatment of osteoarthritis. Bone 37 (2005) 425-430
66. Burch W.M. Calcitonin stimulates growth and maturation of embryonic chick pelvic cartilage in vitro. Endocrinology 114 (1984) 1196-1202
67. Azria M. Possible mechanisms of the analgesic action of calcitonin. Bone 30 (2002) 80S-83S